The earnings call highlighted strong sales growth driven by Dupixent and strategic acquisitions, but also pointed out challenges including mixed trial results for itepekimab and anticipated declines in flu vaccine sales. Despite these challenges, the company remains optimistic about future growth and sustainability efforts.

Company Guidance -

Q3 2025

In the Q2 2025 conference call, Sanofi provided updated guidance, indicating a high single-digit percentage sales growth at constant exchange rates for the full year. This confidence is bolstered by strong performance in Q2, with net sales increasing by 10.1% at constant exchange rates. Key contributors to this growth include double-digit sales increases driven by new launches, vaccines, and Dupixent, which alone saw a 21% rise to EUR 3.8 billion. Sanofi's pipeline remains strong despite some mixed results, with significant contributions from new launches, collectively representing 10% of total sales. The company is also executing a EUR 5 billion share buyback program, with over 80% completed, and continues to anticipate a low double-digit percentage growth in business EPS at constant exchange rates.

Strong Q2 Performance

Sanofi delivered a strong quarter with double-digit sales growth, achieving a 10.1% increase in net sales at constant exchange rates.

Dupixent Sales Surge

Dupixent sales reached EUR 3.8 billion, up 21% in Q2, driven by continued strong demand and improved indications across geographies.

Successful Strategic Acquisitions

Sanofi completed significant acquisitions including Blueprint Medicines, strengthening its position in rare immunology diseases.

Sustainability Recognition

TIME ranked Sanofi as the world's 10th most sustainable company across all industries and #1 in pharma and biotech.

Vaccine Business Growth

Vaccine sales increased by 10.3%, driven by the expansion of Beyfortus and benefiting from the late 2024-2025 flu season.

Sanofi (SNY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SNY Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 24, 2025	2025 (Q3)	1.67 / -	1.549	―	―	―
Jul 31, 2025	2025 (Q2)	0.96 / 0.91	0.939	-3.09% (-0.03)
Apr 24, 2025	2025 (Q1)	0.93 / 0.79	0.953	-17.63% (-0.17)
Jan 30, 2025	2024 (Q4)	0.70 / 0.68	0.899	-24.03% (-0.22)
Oct 25, 2024	2024 (Q3)	1.35 / 1.55	1.349	14.83% (+0.20)
Jul 25, 2024	2024 (Q2)	0.89 / 0.94	0.96	-2.19% (-0.02)
Apr 25, 2024	2024 (Q1)	0.93 / 0.95	1.189	-19.85% (-0.24)
Feb 01, 2024	2023 (Q4)	0.94 / 0.90	0.928	-3.13% (-0.03)
Oct 27, 2023	2023 (Q3)	1.37 / 1.35	1.433	-5.86% (-0.08)
Jul 28, 2023	2023 (Q2)	0.93 / 0.96	0.878	9.34% (+0.08)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SNY Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$49.25	$45.64	-7.33%
Apr 24, 2025	$51.38	$51.89	+0.99%
Jan 30, 2025	$50.54	$52.48	+3.84%
Oct 25, 2024	$50.44	$52.66	+4.40%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.